Previous 10 | Next 10 |
MINNEAPOLIS, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to report initial results on AI-driven models of ovarian can...
A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and s...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services ...
A new study has found that patients with breast cancer who have sufficient levels of vitamin D have better outcomes in the long term. Prof. Song Yao, who is the lead author of the study, suggests that maintaining adequate levels of vitamin D at the time of diagnosis and even after treatmen...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driv...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier ...
Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as ma...
Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space Predictive Oncology is...
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ succes...
Iterum Therapeutics (ITRM) -41% after FDA identifies deficiencies in sulopenem NDA.Arrowhead Pharmaceuticals (ARWR) -23% after pausing mid-stage AROENaC1001 study in cystic fibrosis.Birks Group (BGI) -13%.Alterity Therapeutics (ATHE) -12%.Kintara Therapeutics (KTRA) -8%.Ci...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) fell 20.2% to $0.03 on volume of 382,247,953 shares BurgerFi International Inc (BFI) rose 97.3% to $0.4205 on volume of 313,737,613 shares NVIDIA Corporation (NVDA) rose 0.7% to $113.06 on volume of 292,060...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 22.6% to $0.0461 on volume of 144,150,002 shares Vintage Wine Estates Inc. (VWE) rose 21.5% to $0.0849 on volume of 35,620,484 shares NVIDIA Corporation (NVDA) rose 2.4% to $115.03 on volume of 35,381,...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of it...